Roche Beats Takeda’s Appeal of Voided Hemophilia Drug Patent

Roche Holding AG convinced the Federal Circuit to uphold its January 2022 district court victory canceling a patent that a Takeda Pharmaceutical Co. unit claimed was infringed by Hemlibra, a blockbuster hemophilia treatment sold in the US by Roche’s Genentech Inc.

Chief Judge Kimberly Ann Moore, in a precedential opinion issued Wednesday for a three-judge panel of the US Court of Appeals for the Federal Circuit, rejected the argument by Takeda’s Baxalta Inc. subsidiary that the Delaware federal court was wrong to find US Patent No. 7,033,590 invalid for lack of enablement.

“Specifically, Baxalta argues skilled artisans can ...